PLAC test : measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque. The PLAC test is not a stand-alone test for predicting heart disease or stroke. The test provides supportive information when used with clinical evaluation and other tools for patient risk assessment. Individuals with an elevated PLAC test may be at a two to three times greater risk of having coronary heart disease. Individuals with an elevated PLAC test and elevated blood pressure have a nearly 7-fold increased risk of stroke when compared with patients having lower PLAC test results. It is the only test FDA approved to aid in the detection of both heart disease and stroke due to atherosclerosis. It has been incorporated into the cardiovascular screening and disease prevention program for National Football League retirees.